Development of Escherichia coli rifaximin-resistant mutants: Frequency of selection and stability

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1016-1019

  Ruiz, Joaquim ^a   Mensa, Laura ^a   Pons, Maria J ^a   Vila, Jordi ^b   Gascon, Joaquim ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Diarrhoea; Frequency of mutation; Non absorbable antibiotics

Indexed keywords

BACTERIAL PROTEIN; CHLORAMPHENICOL; CIPROFLOXACIN; NALIDIXIC ACID; RIFAMPICIN; RIFAXIMIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; DILUTION; ENTEROAGGREGATIVE ESCHERICHIA COLI; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI; GENE MUTATION; GENETIC SELECTION; GENETIC STABILITY; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MUTATION; RIFAMYCINS; SELECTION (GENETICS);

EID: 42149084995     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn078     Document Type: Article

References (10)

1. Jiang ZD, Ke S, Palazzini E et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000; 44: 2205-6.
2. Ruiz J, Vensa L, O'Callaghan C et al. in vitro antimicrobial activity of rifaximin against enteropathogens causing travele's diarrhea. Diagn Microbiol Infect Dis 2007; 59: 473-5.
3. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
4. Ruiz J, Jurado A, Garcia-Méndez E et al. Frequency of selection of fluoroquinolone resistant mutants of Neisseria gonorrhoese exposed to gemifloxacin and four other quinolones. J Antimicrob Chemother 2001; 48: 545-8.
5. Miller K, O'Neill AJ, Chopra I. Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J Antimicrob Chemother 2002; 49: 925-34.
6. Xu M, Zhou YN, Goldstein BP et al. Cross-resistance of Escherichia coli RNA polymerase conferring rifampin resistance to different antibiotics. J Bacteriol 2005; 1887: 2763-92.
7. Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Infect 2006; 19: 382-402.
8. Ruiz J. Mechanisms of resistance to quinolones: Target alterations decreased accumulation and DNA Gyrase protection. J Antimicrob Chemother 2003; 51: 1109-17.
9. Ruiz J, Gomez J, Navia MM et al. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis 2002; 42: 257-61.
10. Randall LP, Woodward MJ. The multiple antibiotic resistance (mar) locus and its significance. Res Vet Sci 2002; 72: 87-93.